

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

| | |
|-------------------------------|----------------|
| Name of entity | ABN/ARSN |
| Sigma Pharmaceuticals Limited | 15 088 417 403 |

We (the entity) give ASX the following information.

Information about buy-back

| | | |
|---|------------------------------------|--------------------|
| 1 | Type of buy-back | On-market buy-back |
| 2 | Date Appendix 3C was given to ASXo | 13 September 2012 |

Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

| | Before previous day | Previous day |
|---|--|---------------------------|
| 3 | Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received | 57,627,976 250,000 |
| 4 | Total consideration paid or payable for the shares/units | \$41,707,246 \$184,050 |

Appendix 3E
Daily share buy-back notice

| | Before previous day | Previous day |
|--|---|--|
| 5 If buy-back is an on-market buy-back | Highest price paid: \$0.8525 Lowest price paid: \$0.6250 | Highest price paid: \$0.7400 Lowest price paid: \$0.7300 Highest price allowed under rule 7.33: \$0.8085 |

How many shares/units may still be bought back?

| | |
|---|------------|
| 6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back | 60,752,376 |
|---|------------|

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust’s constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here: _____
 (Director/Company secretary)

Date: 17 July 2013

Print name: SUE MORGAN

== == == == ==
